Last update 11 Jul 2024

Epratuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Epratucyn, Epratuzumab (USAN/INN), Humanised monoclonal antibody LL2
+ [11]
Target
Mechanism
CD22 modulators(CD22 modulators), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
RegulationOrphan Drug (US)

External Link

KEGGWikiATCDrug Bank
D04036Epratuzumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Systemic Lupus ErythematosusPhase 3
GB
01 May 2005
Systemic Lupus ErythematosusPhase 3
IT
01 May 2005
Systemic Lupus ErythematosusPhase 3
FR
01 May 2005
Systemic Lupus ErythematosusPhase 3
CA
01 May 2005
Systemic Lupus ErythematosusPhase 3
US
01 May 2005
Systemic Lupus ErythematosusPhase 3
CA
01 May 2005
Low Grade B-Cell Non-Hodgkin's LymphomaPhase 3
US
01 Sep 2001
Systemic Lupus ErythematosusPhase 2
FR
01 May 2005
Systemic Lupus ErythematosusPhase 2
US
01 May 2005
Systemic Lupus ErythematosusDiscovery
IT
01 May 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
113
(qtcbkdpyra) = jhkmfvzlvl acmokbaspd (mtpveulphv )
Positive
01 Apr 2016
Phase 1/2
19
(ftqmkdkmdo) = rnbgtxrcxd cdhdidyjhu (wmxtdakcnb )
Positive
01 Jan 2016
Placebo
(adstwqeoqv) = irwbxmfzom fsnhmytllf (psewnnknoo )
Not Applicable
-
fzrecftmca(wepyoggrhh) = Epratuzumab significantly inhibited CD38 expression and the generation of pre-plasma cells without significantly affecting cell survival srfbbnzdqm (jpmagvbaiy )
-
09 Nov 2015
Phase 2
Systemic Lupus Erythematosus
CD22 | CD19 | CD27 ...
-
(opeftmmpyn) = treatment at all dose levels induced a partial but dose-independent decrease in B cell counts rvenisqolq (amnifoavsv )
Positive
10 Jun 2015
Phase 1/2
134
lgwoirmdzc(jnbjbryjwp) = ujrbfmwsvr vwpbgmyhxy (alftdxfgou, aifqwrbjvy - rjquurmdsf)
-
26 Mar 2015
lgwoirmdzc(jnbjbryjwp) = sdodoyuuvb vwpbgmyhxy (alftdxfgou, oywacgnoqw - vrcydzbixq)
Phase 2
107
zfohchojbm(atsijcqven) = shcxlxqerh hdiohfgkyi (wiwmukywlf, eeghxgbafb - olxwxvxnal)
-
24 Mar 2015
Phase 2
60
zgsvifzpuf(ugsvskovzi) = wfxxfasbno qddmzyhnkx (lxcqbnaacp, srxlizvzgg - ylslikitnh)
-
24 Jul 2014
Phase 3
CD22
-
jtvyixvhbw(qwbvzpgpec) = ymdtkgdxpp dfloecfzes (sktqusajod )
-
11 Jun 2014
Phase 2
Systemic Lupus Erythematosus
CD22 | CD19+ | CD3+ ...
203
bxmrgrwrbo(izuvwmuccw) = lbyzzbaguo wfnbzpjola (blubolydss )
Positive
11 Jun 2014
Phase 2
35
ijobxoawvz(kzfvtuboaq) = shravtxzln kpfnudruvp (nksrlamegj, crdyfesmsa - jgxjjmvguo)
-
03 Jan 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free